Answers are grounded in this paper and cite their sources.
Case report details clinical outcome and treatment of a patient with spindle cell rhabdomyosarcoma, suggesting molecular diagnostics may inform future management.
Fusion-driven extraosseous spindle cell rhabdomyosarcoma (SRMS) is a rare and recently recognized subcategory of rhabdomyosarcoma, with limited data on optimal management and clinical outcomes. We present the clinical course and long-term outcome of a unique case of SRMS harboring a novel MEIS1-FOXO1 gene fusion diagnosed in a 40-year-old female. The case was successfully managed with a treatment regimen including surgery, radiation, and chemotherapy following a low-risk rhabdomyosarcoma paradigm. This report highlights the importance of molecular diagnostics in identifying rare gene fusions in SRMS and may help guide the management of future patients.
No takes yet. Share an insight, caveat, or question.
Mathew et al. (2025) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: